Category: Analysis - Page 14 - Psychedelic Alpha

Tryp Therapeutics Launches Clinical Trials to Investigate Psilocybin for Over-Eating Disorders

Post published:February 16, 2021
Post category:Analysis Editorial

Read more about the article UK Regulators Approve Beckley Psytech Study of Psilocybin for Debilitating Headache Condition

UK Regulators Approve Beckley Psytech Study of Psilocybin for Debilitating Headache Condition

Post published:January 27, 2021
Post category:Analysis News

Read more about the article North American Psychedelics Index Published: Which Companies Will Be in the First Psychedelic ETF?

North American Psychedelics Index Published: Which Companies Will Be in the First Psychedelic ETF?

Post published:January 21, 2021
Post category:Analysis News

Read more about the article The Psychedelic Renaissance in 2020

The Psychedelic Renaissance in 2020

Post published:December 30, 2020
Post category:Analysis Editorial

Read more about the article First Psychedelic ETF Expected to Launch January 2021 (NEO:PSYK)

First Psychedelic ETF Expected to Launch January 2021 (NEO:PSYK)

Post published:December 28, 2020
Post category:Analysis News

Read more about the article Canada to Consider Allowing Psychedelic-Assisted Therapy under Special Access Program Amendment

Canada to Consider Allowing Psychedelic-Assisted Therapy under Special Access Program Amendment

Post published:December 12, 2020
Post category:Analysis News

Read more about the article Cybin Corp Establishes a Firm Foothold in the Psychedelic Sector with Historic CAD$45 Million Raise

Cybin Corp Establishes a Firm Foothold in the Psychedelic Sector with Historic CAD$45 Million Raise

Post published:October 30, 2020
Post category:Analysis Editorial

Read more about the article Psilocybin Patents: Predictors and Drivers of Company Value?

Psilocybin Patents: Predictors and Drivers of Company Value?

Post published:September 26, 2020
Post category:Analysis

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.